Enhance your understanding of the use of immunotherapy in advanced lung cancer with videos and slides from our satellite symposium at the European Lung Cancer Congress 2018 in Geneva. The successes and challenges of checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) are discussed, as well as the next steps in the integration of immunotherapy combinations in NSCLC management.
0.75 AMA PRA Category 1 Credits™
May 15, 2018
May 15, 2019
Use of immune checkpoint inhibitors in advanced NSCLC: Successes and challenges
Fabrice Barlesi, MD, PhD
Next steps in NSCLC management: Integrating immunotherapy combinations in clinical practice
Martin Reck, MD, PhD
Solange Peters, MD, PhD
Fabrice Barlesi, MD, PhDAssitance Publique
Hôpitaux De Marseille
Solange Peters, MD, PhDUniversity of Lausanne
Martin Reck, MD, PhDLungenClinic Grosshansdorf
This educational activity is specifically designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer.
After successful completion of this educational activity, participants should be able to:
- Select the optimal immunotherapy approach for patients with advanced NSCLC, and assess the role of PD-L1 expression and other emerging biomarkers for response to immunotherapy
- Explain patterns of response to immunotherapy and manage specific immune-related adverse events
- Describe emerging immunotherapy combination strategies and how to integrate them in clinical practice
This educational activity is supported by F. Hoffmann-La Roche Ltd.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Barlesi has disclosed that he has received honoraria or consultation fees from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Clovis, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Merck, Novartis, MSD, Pierre Fabre, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Peters has no relevant financial relationship to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Reck has disclosed that he has received honoraria or consultation fees from AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, and Roche/Genentech. He has also participated in company-sponsored speaker’s bureaus for AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, and Roche/Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.